Fred Hutchinson Cancer Center Receives $710 Million Donation from Bezos Family, Plans Expansion

The gift supports the organization’s efforts to accelerate the pace and breadth of medical breakthroughs in cancer and infectious disease.

By HFT Staff

The Bezos family has committed $710.5 million over the next decade to accelerate Fred Hutchinson Cancer Center’s multifaceted approach to scientific discovery. The gift supports the organization’s efforts to accelerate the pace and breadth of medical breakthroughs in cancer and infectious disease by tapping the full potential of today’s science.  

The center plans to further develop systems that stimulate the ability of discoveries in one area of science to advance others, both internally and via global collaborations with new and established partners. 

To enable that vision, the gift will support the following key priorities over the next 10 years: 

  • Research facilities ($225 million). This funding will go toward the construction of a new, 390,000-square-foot research building on the Seattle campus that will house the Stuart and Molly Sloan Precision Oncology Institute. The building will provide space for researchers, their teams and new technologies and equipment.  
  • Recruitment ($300 million). This gift will enable the center to recruit about 36 new researchers from a variety of scientific areas, including early- and mid-career researchers and senior scientists. The funding includes resources for lab space, equipment, and technology for its collaborative research environment. 
  • Clinical research infrastructure ($149.5 million). Expansion of institution-wide clinical research capabilities will allow for more collaborations between bench scientists and clinicians, more clinical trials to be available to more patients, and increased study enrollment of individuals from diverse backgrounds.  
  • Expanding immunotherapy research ($36 million). Funding for the Immunotherapy Integrated Research Center will expand immune-based strategies for treating cancer and our understanding of underlying biological mechanisms for how immunotherapy works. 

October 14, 2022

Topic Area: Construction , Industry News , Maintenance and Operations

Recent Posts

Avoiding Problems When Disinfecting Hospital Surfaces

Guidance on ensuring success when it comes to the most effective products and procedures.

Turner Construction Company Tops Out McGivney Tower

The entire 507,000 square foot project is expected to be finished in late 2026.

The Advantages of Access Control Technology Over Traditional Formats

Access control manufacturers discuss the technology’s potential benefits.

Preparing for the Hazards of Winter Weather

Winter is here and healthcare facilities must be ready for inclement weather to prevent slips and falls.

The Leapfrog Group Announces 2023 Top Hospital and Top ASC Award Winners

132 hospitals earned the Top Hospital Award, and 27 ambulatory surgery centers earned the Top ASC Award.


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.